Key points from article :
Amplifier Therapeutics, a company under Cambrian Bio, has started a Phase 1B clinical trial for ATX-304, a drug designed to activate AMPK, which regulates energy in the body. This trial aims to explore the drug's safety and how it behaves in the body while also assessing its effects on metabolic health and muscle function.
The study is an 8-week, double-blind, randomized, placebo-controlled trial involving overweight or obese prediabetic participants in the European Union. ATX-304 targets AMPK, a key sensor that helps the body produce energy, which becomes harder to activate as people age, potentially helping with cardiometabolic and aging-related diseases.
James Hall, CEO of Amplifier Therapeutics, emphasized the drug's potential to improve patient outcomes in chronic conditions not fully addressed by current treatments. Alongside the trial, Amplifier raised $33.25 million in Series A funding from RA Capital Management and Future Ventures to speed up research and development. The company is working closely with Cambrian Bio to push forward the clinical program.
